Paradigm Biocapital Advisors LP Arcellx, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.47 Billion
- Q2 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,848,095 shares of ACLX stock, worth $329 Million. This represents 8.59% of its overall portfolio holdings.
Number of Shares
3,848,095
Previous 3,818,095
0.79%
Holding current value
$329 Million
Previous $266 Million
20.02%
% of portfolio
8.59%
Previous 9.96%
Shares
7 transactions
Others Institutions Holding ACLX
# of Institutions
176Shares Held
45.7MCall Options Held
53.6KPut Options Held
53.7K-
Perceptive Advisors LLC New York, NY3.89MShares$332 Million6.21% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$320 Million19.51% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$300 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$200 Million56.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.3MShares$196 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.74B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...